Plain-English translation of NCT07687459 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a Phase 3 clinical trial testing a medication called Rentosertib (INS018_055) in adults with idiopathic pulmonary fibrosis—a serious lung disease where healthy lung tissue gradually becomes scarred and stiff. You would take the medication by mouth once daily for 52 weeks while researchers track whether this treatment slows lung damage and learn about its safety. Half of the participants will receive the actual medication, and half will receive a placebo (a dummy pill that looks identical but contains no active drug).
Idiopathic pulmonary fibrosis is a progressive disease with limited treatment options, and current medications don't work for everyone or don't slow the disease enough. This trial exists to see whether this new medication might offer patients a better way to preserve their lung function and slow disease progression.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will take a tablet by mouth once every day for 52 weeks (one year). You will be randomly assigned to receive either the actual medication or a placebo—neither you nor your doctor will know which one you're taking. During the study, you will have regular clinic visits where your doctors will check your lung function with breathing tests, take chest imaging scans, and draw blood to monitor how you're doing and watch for any side effects. The study will take place at medical centers that specialize in lung disease.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
China